Answers are grounded in this paper and cite their sources.
Retrospective analysis of the treatment results of 156 patients with locally advanced and disseminated esophageal squamous cell carcinoma was performed. The patient group included 124 (79.3 %) men (median age 64 years) and 32 (20.5 %) women (median age 63.4 years). Metastases were found primarily in the lymph nodes – 136 (87.2 %) cases, lungs – 44 (28.2 %) cases, liver – 38 (24.4 %) cases. The patients received treatment with a two-component drug combination: paclitaxel + carboplatin (ТР), or a four-component combination: docetaxel + cisplatin + leucovorin + 5-fluorouracil (mDCF). The mDCF combination showed higher rates of toxicity: hematogenic (neutropenia) and non-hematogenic (asthenia, weight loss, lower limb edema) complications. In 37 (23.7 %) patients, grade III and IV dysphagia were diagnosed. It was managed by endoscopic installation of self-expanding stents. Currently, despite toxic side symptoms, both schemes are safe and are the most commonly prescribed for locally advanced and disseminated esophageal squamous cell carcinoma.
No takes yet. Share an insight, caveat, or question.
Victor V. Sokolovskiy (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: